PharmaCyte Biotech Inc (PMCB) — Financial Flexibility Index
PharmaCyte Biotech Inc (PMCB) has a Financial Flexibility Index of -0.05x as of January 2026. Free cash flow of $-786.85K (operating CF $-786.85K minus capex $0.00) represents 0% of total liabilities ($16.47 Million). Check PharmaCyte Biotech Inc (PMCB) strategic asset index to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
PharmaCyte Biotech Inc Financial Flexibility Index (2002–2025)
Historical Financial Flexibility Index trend for PharmaCyte Biotech Inc across 24 annual periods. See PharmaCyte Biotech Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for PharmaCyte Biotech Inc (2002–2025)
Year-by-year free cash flow to debt coverage for PharmaCyte Biotech Inc. For the full company profile including market capitalisation, see PharmaCyte Biotech Inc market capitalisation.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.91x | $-2.98 Million | $-2.98 Million | $3.28 Million | ▼ -761.2% |
| 2024 | -0.11x | $-2.15 Million | $-2.15 Million | $20.39 Million | ▲ +98.4% |
| 2023 | -6.47x | $-3.79 Million | $-3.79 Million | $586.58K | ▼ -10.6% |
| 2022 | -5.85x | $-4.12 Million | $-4.12 Million | $704.37K | ▼ -27.2% |
| 2021 | -4.60x | $-3.33 Million | $-3.33 Million | $724.78K | ▼ -111.8% |
| 2020 | -2.17x | $-2.34 Million | $-2.34 Million | $1.08 Million | ▲ +44.0% |
| 2019 | -3.87x | $-2.88 Million | $-2.88 Million | $742.85K | ▲ +50.9% |
| 2018 | -7.89x | $-5.08 Million | $-5.08 Million | $644.17K | ▼ -37.0% |
| 2017 | -5.76x | $-3.34 Million | $-3.34 Million | $580.25K | ▲ +15.6% |
| 2016 | -6.82x | $-4.35 Million | $-4.35 Million | $637.64K | ▼ -200.8% |
| 2015 | -2.27x | $-4.56 Million | $-4.56 Million | $2.01 Million | ▼ -143.7% |
| 2014 | 5.18x | $1.94 Million | $-1.56 Million | $373.67K | ▲ +5144.3% |
| 2013 | -0.10x | $-390.43K | $-390.43K | $3.80 Million | ▼ -73.1% |
| 2012 | -0.06x | $-259.29K | $-259.29K | $4.37 Million | ▼ -7.0% |
| 2011 | -0.06x | $-220.15K | $-225.23K | $3.97 Million | ▲ +82.0% |
| 2010 | -0.31x | $-974.06K | $-974.06K | $3.15 Million | ▲ +25.3% |
| 2009 | -0.41x | $-1.18 Million | $-1.19 Million | $2.85 Million | ▲ +93.6% |
| 2008 | -6.48x | $-1.17 Million | $-1.19 Million | $180.56K | ▼ -323.2% |
| 2007 | 2.90x | $344.92K | $-351.60K | $118.81K | ▲ +297.3% |
| 2006 | -1.47x | $-1.06 Million | $-1.07 Million | $723.89K | ▲ +12.0% |
| 2005 | -1.67x | $-2.73 Million | $-2.80 Million | $1.63 Million | ▼ -212.5% |
| 2004 | -0.53x | $-176.03K | $-221.03K | $329.13K | ▲ +96.4% |
| 2003 | -14.84x | $-37.46K | $-37.46K | $2.52K | ▼ -574.6% |
| 2002 | -2.20x | $-21.99K | $-21.99K | $10.00K | — |